Hold MDLZ at $62.18 — symmetric risk/reward at 18.5x P/E with momentum cooling at 52-week highs; wait for confirmation triggers
The HOLD recommendation rests on five evidence points: (1) sequential P&L deterioration in Q2 2026 with operating margin at multi-quarter lows of 8.5% (down 460bps from Q3 2025's 13.1%) confirms recovery is not yet in printed numbers; (2) technical setup at genuine inflection with price at 52-week highs while MACD line is below signal with histogram at -0.04 indicating momentum rollover; (3) symmetric risk/reward at current levels (~$4.50 upside to 52-week high vs ~$4.32 downside to 200 SMA); (4) the 3.24% dividend yield provides a structural floor that argues against selling while technical and fundamental uncertainty argues against adding; (5) the bull case relies entirely on forward EPS estimates materializing while the bear case rests on the P&L as currently printed — this is a textbook "wait for resolution" configuration. Stop at $59.30 remains intact (below 50 SMA at $60.92 and Bollinger lower at $59.28) and should not be tightened further as ATR routine volatility probes stops placed inside 1 ATR.
| Position | Action |
|---|---|
| Partial add on pullback to 50 SMA at $60.92 with RSI resetting into 48-50 and MACD histogram turning positive | Add ≤25% of position size at half-normal sizing |
| Partial add on confirmed breakout above $64.20 on volume ≥12M shares with RSI >60 | Add ≤25% of position size at half-normal sizing |
| Current price level with 18.5x forward P/E and MACD bearish cross at 52-week highs | No action — do not add |
| Forward EPS stabilizes at consensus $3.36 recovery | Resume normal sizing after confirmation |
MDLZ is a defensive compounder positioned for an EPS inflection from $1.64 to $3.36 (implied ~105% growth), driven by Tate's premium brand outpacing the cookie category by 150%, emerging markets generating well over 40% of revenue, and a defensive rotation bid at 18.5x forward P/E with a 3.24% yield.
| Indicator | Value | Signal |
|---|---|---|
| Close | 62.18 | neutral |
| Open | 61.20 | neutral |
| High | 62.26 | neutral |
| Low | 60.92 | neutral |
| Volume | 6,423,466 | neutral |
| 10 EMA | 62.07 | neutral |
| 50 SMA | 60.92 | bullish |
| 200 SMA | 57.86 | bullish |
| RSI(14) | 53.45 | neutral |
| Bollinger Middle | 61.74 | neutral |
| Bollinger Upper | 64.20 | bullish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed breakout above $64.20 on volume ≥12M shares with RSI confirming above 60
Then: Partial add ≤25% of position size at half-normal until forward EPS stabilizes
↩ rebuts: “Bear concerns about China softness”
EV: bull target: through $64.20 (Bollinger upper) toward fresh highs; risk line: $59.30 · concedes: PEG ratio of 1.02 suggests stock is essentially fairly valued relative to growth, not cheap; Stock near 52-week high (93%) limits near-term upside visibility; Single quarter of sequential revenue moderation (Q2 8.5% operating margin vs Q3 2025's 13.1%) reflects input cost timing and cocoa hedge accounting; TTM earnings are depressed at $1.64 vs $3.36 forward consensus
MDLZ is a stock to own from the sidelines, not to add to — the bull is buying a story while the bear is reading the P&L, with risk/reward asymmetric to the downside given declining margins, deteriorating cash generation, and negative technical momentum.
· concedes: HOLD is appropriate for existing holders who bought below $58 and are collecting the dividend; Defensive rotation is a valid near-term tactical thesis, but likely has already peaked; At $62.18, upside to 52-week high of $66.65 (~$4.50, ~7%) is roughly symmetric to downside to 200 SMA at $57.86 (~$4.32, ~7%), though asymmetric if Q3 disappoints; 3.24% dividend yield and capital return is the only part of the thesis actually working right now; Tate's at 2.5x category growth is a defensive beachhead, even if immaterial at consolidated level; Alternative defensives (PG, TGT, KO) have similar yield profiles with less leverage risk
→ vs conservative: Net debt of $19.5B against $79B market cap is not a stretched balance sheet; 82% debt-to-equity is textbook high but negative working capital is a feature in consumer staples
→ vs conservative: Higher for longer rates actually benefit defensive names with proven pricing power like MDLZ; defensive rotation to MDLZ, KO, and TGT hitting 52-week highs is a regime, not a fluke
→ vs conservative: OCF dip in Q1 2026 was working capital timing, not structural deterioration; Q4 2025 alone generated $2B FCF
→ vs neutral: Risk-reward framing of $4.50 upside vs $4.30 downside is mathematically wrong; target of $74-$77 implies $12-$15 upside not $4.50
→ vs neutral: Current price anchoring is static analysis; forward earnings setup and re-rating to 22-23x forward earnings changes the math materially
→ vs neutral: MACD histogram reset from +0.46 to -0.04 is a healthy reset after 4% spike, not a warning sign; RSI cooling from 66 to 53 without breaking 50 is constructive
→ vs neutral: Consolidation is being read as distribution or exhaustion when it is actually a coiled spring and bull flag formation
| Bollinger Lower | 59.28 | bearish |
| MACD | 0.49 | neutral |
| Signal | 0.53 | neutral |
| Histogram | -0.04 | bearish |
| ATR(14) | 1.61 | neutral |
| RSI Peak (2026-07-29) | 66.39 | bullish |
| MACD Histogram Peak (2026-07-30) | +0.46 | bullish |
| July 29 High | 64.99 | bullish |
Support: 60.92 · 59.28 · 57.86 · 53.44 | Resistance: 64.99 · 64.2 · 62.26
MDLZ exhibits a confirmed medium-term uptrend with price above all moving averages (Price > 10 EMA > 50 SMA > 200 SMA), but short-term momentum has cooled significantly. MACD histogram rolled from +0.46 (2026-07-30) to -0.04, indicating loss of upside momentum rather than bearish reversal. RSI reset from overbought 66.39 to neutral 53.45, providing room for another leg higher. Volume at 6.4M is below the 7-10M typical range, consistent with post-rally consolidation rather than distribution. Support converges at $60.92 (50 SMA) and $59.28 (Bollinger Lower), while resistance sits at $64.20 (Bollinger Upper) and $64.99 (recent swing high). Trade recommendation is HOLD for existing positions; new entries should await either a pullback to $60.50-$60.90 or a breakout above $64.20-$64.99 on volume ≥12-15M.
Market Cap
$79.36B
P/E (TTM)
37.91
Forward P/E
18.50
PEG Ratio
1.02
Price to Book
2.99
EPS (TTM)
$1.64
Forward EPS
$3.36
Dividend Yield
3.24%
Beta
0.404
52-Week High
$66.65
52-Week Low
$51.20
50-Day Average
$61.09
200-Day Average
$58.64
TTM Revenue
$39.67B
Gross Profit
$12.36B
Gross Margin
31.1%
EBITDA
$6.08B
EBITDA Margin
15.3%
Operating Margin
21.98%
Net Income (TTM)
$3.52B
Net Margin
8.86%
ROE
13.34%
ROA
4.12%
Total Assets
$71.12B
Total Liabilities
$45.32B
Stockholders' Equity
$25.75B
Tangible Book Value
($18.01B)
Total Debt
$21.62B
Net Debt
$19.50B
Cash & Equivalents
$1.52B
Goodwill
$24.23B
Other Intangibles
$19.53B
Net PPE
$11.29B
Inventory
$4.08B
Receivables
$5.38B
Accounts Payable
$9.74B
Current Ratio
0.60
Debt/Equity
0.83
TTM Free Cash Flow
$2.25B
Q1 2026 Operating Cash Flow
$467M
Q4 2025 Free Cash Flow
$1,999M
Annual Dividends
~$2.5B
Annual CapEx
~$1.2B
Book Value
$20.80
Q2 2026 Revenue
$10.08B
Q2 2026 Operating Income
$860M
Q2 2026 Net Income
$560M
Q2 2026 Diluted EPS
$0.40
Q1 2026 Revenue
$10,496M
Q1 2026 Operating Income
$979M
Q1 2026 Net Income
$560M
Q1 2026 Diluted EPS
$0.44
Strengths
Concerns
Mondelez International is a global confectionery and snack leader with iconic brands (Oreo, Cadbury, Toblerone, Milka) operating in 150+ countries. The stock shows a striking valuation disconnect with a trailing P/E of 37.91 versus a forward P/E of 18.50, implying the market expects earnings to roughly double from depressed recent levels. The company generates $2.25B in TTM free cash flow supporting its 3.24% dividend yield, though Q2 2026 results showed margin pressure (operating margin declining to 8.5%) and sequential revenue softness. With $19.5B in net debt against negative tangible book value, the investment thesis hinges on cocoa cost stabilization, emerging market recovery (especially China), and continued share buybacks. Best suited for income-oriented, risk-averse investors seeking defensive consumer staples exposure.
Macro: Higher-for-longer rate regime: Polymarket pricing 86% probability of NO Fed rate cuts in 2026 (down 2pp week-over-week), with 0% probability of 6+ cuts — a regime that favors defensive cash flows with pricing power over high-multiple growth. Soft landing base case intact: US recession odds at 8% (down 1pp WoW), UK at 16%, Japan at 28%, with tail risk low. Tariff overhang persists: US-China deal by Aug 31 only 8% priced; Canada tariff hike by YE26 at 46%. Market rotation visible: mixed US equities post-inflation data and AI earnings, rotation away from crowded AI megacaps toward defensives. Walmart showing strength but RBC cautious on big-box comp sales — argues for premium/specialty brands (where Tate's lives) to keep taking share.